Absolute Lymphocyte Count May Help Monitor Neurologic Events Following Cilta-Cel Therapy in RRMM - Oncology Nurse Advisor A retrospective study investigated the association of biomarkers pre- and post-cilta cel infusion with neurocognitive TEAEs and cranial nerve palsy in pts with RRMM.

Measuring certain biomarkers, including ALC, within the first 2 weeks of administering cilta-cel, a CAR T-cell therapy, may help identify patients with R/R #multipleMyeloma who are at higher risk of developing neurologic AEs.

https://bit.ly/3M9wFnJ

#JADPRO25

MonumenTAL-1: Talquetamab Shows Durable Responses, Tolerable Safety at 36-Month Follow Up in RRMM - Oncology Nurse Advisor Researchers presented efficacy and ongoing safety data from MonumenTAL-1, a phase 1/2 study assessing talquetamab in patients with multiple myeloma.

Patients with R/R #multipleMyeloma treated with talquetamab, an anti-GPRC5D bispecific antibody, continue to show deep, durable responses with tolerable safety at extended follow up of 30-38 months. Presented at #JADPRO25, from @cancertherapyadv.bsky.social.

https://bit.ly/49IdE5A

Neurologic PNS Screening Uptake in Patients With SCLC Low in US - Oncology Nurse Advisor Updated NCCN SCLC guidelines recommend testing patients with suspected PNS; however, researchers found screening uptake in the US is low.

Screening for neurologic paraneoplastic syndromes among patients with #SCLC remains low in the United States. Presented at #JADPRO25.

https://bit.ly/3LA6juD

#lcsm #LungCancerAwarenessMonth #LCAM